Search clinical trials for: Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)

Total 569 results

Osivax
Novotech (Australia) Pty Limited; Harmony Clinical Research; Northern Beaches...

Completed

Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.

Influenza

Australia
Sanofi Pasteur, a Sanofi Company

Terminated

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Influenza Immunization

United States, Denmark, Poland, Spain
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Seasonal Influenza

Spain, United States, Denmark, Poland, United Kingdom, Germany, Canada, Taiwan, Bulgaria, Netherlands, Estonia
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Seasonal Influenza

Philippines, Australia, Colombia, Argentina, Panama
Green Cross Corporation

Unknown

A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study

Influenza

Korea, Republic of
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea

Influenza (Healthy Volunteers)

Korea, Republic of
St. Petersburg Research Institute of Vaccines and...

Recruiting

Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children

Vaccine Reaction | Influenza | Influenza, Human | Influenza Viral Infections

Russian Federation
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above

Influenza

Brazil
ModernaTX, Inc.

Active, not recruiting

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults (IGNITE P303)

Seasonal Influenza

United States
Johns Hopkins Bloomberg School of Public Health
Columbia University; Sanofi Pasteur, a Sanofi Company; Institute of Epidemiology... and other collaborators

Completed

Pregnancy, Arsenic and Immune Response (PAIR)

Influenza | Vaccine Response Impaired | Micronutrient Deficiency | Arsenic--Toxicology | Immunologic Disorders Complicating Pregnancy

Bangladesh
Crucell Holland BV

Completed

Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults

Influenza

Belgium
Emory University

Recruiting

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Pneumococcal Infections

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Influenza Immunization

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Influenza Immunization

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Influenza Immunization

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico
Sinovac Biotech Co., Ltd
Pontificia Universidad Catolica de Chile; Sinovac Biotech Co., Ltd

Completed

Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Seasonal Influenza

Philippines, Chile
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

Influenza

United States, Germany, Poland, Spain, Czechia, Bangladesh, France
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets (FLU-TW)

Influenza

United States
Protein Sciences Corporation

Completed

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

Influenza

United States
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra

Influenza

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India

Influenza

India
Hualan Biological Engineering, Inc.

Completed

Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine

Human Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Adults

Influenza

United States
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

Influenza, Human

United States
Duke University
Boston Medical Center; Centers for Disease Control and Prevention; Children's...

Completed

Safety of RIV4 Versus IIV4 in Pregnant Women

Safety | Birth Outcomes | Adverse Event Following Immunisation

United States
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland
Seqirus

Completed

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Influenza, Human

United States, Estonia, Germany
International Centre for Diarrhoeal Disease Research...
Centers for Disease Control and Prevention; Institute of Epidemiology, Disease... and other collaborators

Recruiting

Cost-effectiveness of the Influenza Vaccination

Influenza Vaccine | Vaccination | Cost-Effectiveness

Bangladesh
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age

Influenza

Canada, Honduras, Dominican Republic
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Herpes Zoster

Germany, Canada, United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Withdrawn

Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood (FLU-LN)

Influenza

United States
Protein Sciences Corporation

Completed

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

Influenza

United States
Kaiser Permanente
Seqirus

Recruiting

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Influenza | Community-acquired Pneumonia | Cardiovascular Events

United States
Centers for Disease Control and Prevention

Withdrawn

Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya

Tetanus | HIV | Malaria | Influenza, Human | Polio

Kenya
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response (HIPCVAX-010S)

Influenza A Subtype H5N1 Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Response to Influenza Vaccine During Pregnancy (FLU-PG)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (SLVP033)

Hepatitis A | Influenza | Healthy Adults | Typhoid

United States
National Institute of Allergy and Infectious Diseases...

Completed

Development of Childhood Anti-Influenza Immunity

Influenza | Influenza Immunisation

United States
Duke University
Centers for Disease Control and Prevention; Children's Hospital Medical Center...

Completed

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women (Tdap/IIV)

Pregnancy

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)

Influenza

Philippines
Sanofi

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Influenza Immunization (Healthy Volunteers)

Finland, Germany
Center for Disease Prevention and Control of Beijing...

Completed

Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
University Hospital, Ghent
CEVAC Core Lab, University Ghent; Max Planck Institute for Infection Biology... and other collaborators

Completed

Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults

Prevention of Influenza

Belgium

3

Subscribe